Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas

NCT00869284 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: CEEP regimen
PROCEDURE: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]